Skip to main content

GOLDMAN SACHS GROUP INC

Position in AVXL — Anavex Life Sciences Corp.

CIK 886982 NEW YORK, NY

Position in AVXL

as of Mar 31, 2026 · filed May 15, 2026
Position Value
$2,469,615
-$638,150 QoQ
Shares Held
804,435
-7.9% QoQ
Ownership
0.868%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
not a current holder
Holding Since
Mar 2020
25 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in AVXL Over Time

Shares Held

Position Value (USD)

Derivatives in AVXL

reported options exposure · as of Sep 30, 2024
CallValue
$0
CallShares
0
PutValue
$894,032
PutShares
157,400

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Mar 31, 2026

GOLDMAN SACHS GROUP INC holds $10,294,260,512 across 365 Biotechnology names. AVXL ranks #204 (0.0% of the industry book) .

# Ticker Company Shares Value (USD) Open

All Filings in AVXL

Export CSV
28 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $2,469,615 804,435
2025-12-31 $3,107,765 872,968
2025-09-30 $2,700,161 303,389
2025-06-30 $2,708,651 293,780
2025-03-31 $3,532,033 411,659
2024-12-31 $5,783,930 538,541
2024-09-30 $894,032 157,400
2024-09-30 $3,760,738 662,102
2024-06-30 $1,929,227 457,163
2024-03-31 $2,719,138 534,212
2023-12-31 $2,481,794 266,573
2023-09-30 $1,447,661 221,017
2023-06-30 $2,603,225 320,200
2023-03-31 $2,163,925 252,500
2023-03-31 $5,757,428 671,812
2022-12-31 $2,236,290 241,500
2022-12-31 $6,508,899 702,905
2022-09-30 $3,192,109 309,313
2022-06-30 $3,582,177 357,860
2022-03-31 $5,401,184 438,764
2021-12-31 $6,597,262 380,465
2021-09-30 $1,932,747 107,674
2021-06-30 $2,060,074 90,117
2021-03-31 $2,031,286 135,872
2020-12-31 $185,841 34,415
2020-09-30 $109,645 24,098
2020-06-30 $105,716 21,487
2020-03-31 $130,334 41,376